Parachute or Unicorn: The Founder’s Dilemma

Catch the Full Episode

In an industry that confuses algorithmic sophistication with real progress, this conversation cuts straight to the point.

For the first episode of The End podcast, Biorce CEO Pedro Coelho sits down with Daniel Lou, ex-McKinsey, ex-Roche, and founder of Revelo, a platform accelerating clinical trials from recruitment to regulatory endpoints.

They discuss:

• Why most AI solutions in clinical trials fail when regulators get involved

• The mistakes pharma keeps repeating with technology adoption

• How to design clinical trial protocols that work in the real world

• What makes clinical trial tech companies succeed — or stall

This is not a hype-driven AI conversation. It’s a grounded discussion about execution, incentives, and the uncomfortable truths shaping the future of clinical trials.

In an industry that confuses algorithmic sophistication with real progress, this conversation cuts straight to the point.

They discuss:

• Why most AI solutions in clinical trials fail when regulators get involved

• The mistakes pharma keeps repeating with technology adoption

• How to design clinical trial protocols that work in the real world

• What makes clinical trial tech companies succeed — or stall

This is not a hype-driven AI conversation. It’s a grounded discussion about execution, incentives, and the uncomfortable truths shaping the future of clinical trials.